Daily Endocrinology Research Analysis
Analyzed 73 papers and selected 3 impactful papers.
Summary
Three studies advance endocrinology and metabolism this cycle: mechanistic work reveals an epigenetic "memory of obesity" in CD4 T cells that sustains immune dysregulation after weight loss; a large UK Biobank cohort shows that concentrating weekly moderate-to-vigorous activity into 1–2 days confers microvascular protection similar to regular activity in type 2 diabetes or prediabetes; and a population study links low IGF-1 with heightened cardio-kidney risk in MASLD, supporting precision risk stratification.
Research Themes
- Epigenetic imprinting and immunometabolism in obesity
- Flexible physical activity patterns and microvascular risk in diabetes
- IGF-1–guided cardio-kidney risk stratification in MASLD
Selected Articles
1. DNA methylation-mediated memory of obesity in CD4 T lymphocytes perpetuates immune dysregulation.
This mechanistic study shows that obesity imprints CD4 T cells via persistent DNA methylation, delaying the restoration of adaptive immune homeostasis for years after weight loss. Pathway analyses implicate autophagy and immune senescence, with palmitate as a potential driver of epigenetic change, and identify Stk26 and Cdkn1c as targetable nodes.
Impact: It introduces an epigenetic mechanism of ‘obesity memory’ in human T cells and nominates actionable pathways, reframing why weight loss alone may not normalize immune function.
Clinical Implications: Weight loss interventions may need adjuncts that target autophagy/senescence or epigenetic remodeling to restore immune homeostasis. Monitoring immune/epigenetic markers could inform relapse risk.
Key Findings
- Obesity induces persistent DNA methylation changes in CD4 T cells, delaying immune homeostasis for years after weight loss.
- Autophagy and immune senescence pathways are implicated; palmitate can drive epigenetic alterations in CD4 T cells.
- Candidate targets (Stk26, Cdkn1c) linked to autophagy/senescence were identified as potential intervention nodes.
Methodological Strengths
- Integrative epigenomic analyses linking DNA methylation to functional pathways (autophagy, senescence).
- Use of human immune cells with mechanistic validation of fatty-acid–induced epigenetic alterations.
Limitations
- Causality and clinical translatability remain to be proven in interventional studies.
- Sample size, cohort composition, and longitudinal kinetics are not detailed in the abstract.
Future Directions: Test whether targeting autophagy/senescence or epigenetic modifiers restores immune homeostasis post–weight loss; longitudinal studies to map methylation recovery trajectories and relapse.
Obesity represents a major global healthcare crisis, with childhood obesity rising at an alarming rate. Children with obesity are highly likely to carry it into adulthood, bringing numerous associated health risks. Even more troubling is the emerging understanding of "obesity memory", which contributes to the frequent issue of weight regain. Here, we show that obesity imprints CD4 T cells through DNA methylation, leading to a long-time lag, spanning years, before adaptive immune homeostasis is restored after weight loss. Differential DNA methylation analysis highlights autophagy and immune senescence as potential key mechanisms underpinning this memory of obesity in CD4 T cells. In addition, particularly palmitate could be a key saturated fatty acid that can contribute to epigenetic alterations in CD4 T cells, potentially perpetuating this altered state. We identify molecular candidates (i.e., Stk26 and Cdkn1c) underpinning key cell functions (autophagy and immune senescence) that could be targeted to promote a return to immune homeostasis alongside weight loss. These findings raise the possibility that targeting such pathways could support the restoration of immune homeostasis alongside weight loss therapies.
2. Serum IGF-1 and the Risk of Cardio-Kidney Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease.
In 214,512 UK Biobank participants followed for 13 years, MASLD predicted higher cardio-kidney events, with the strongest risks in those with low serum IGF-1. Associations were consistent across subgroups and extended to CKD and 3P-MACE, suggesting IGF-1 augments risk stratification beyond standard metabolic factors.
Impact: This very large, long-term cohort shows that low IGF-1 identifies MASLD patients at highest cardio-kidney risk, enabling precision prevention and monitoring strategies.
Clinical Implications: In MASLD, measuring IGF-1 could refine cardio-renal risk stratification and guide intensity of preventive therapies and surveillance, especially in younger patients and those with albuminuria.
Key Findings
- MASLD increased cardio-kidney outcomes across IGF-1 tertiles, with the strongest effect in the lowest IGF-1 group (aHR 1.24 for composite CKO).
- Similar risk patterns were observed for incident CKD (aHR 1.35) and 3P-MACE (aHR 1.26) in the lowest IGF-1 tertile.
- MASLD–IGF-1 interaction was significant (P=0.014), and associations were consistent across sex, BMI, and diabetes, stronger in participants <65 years and those with baseline albuminuria.
Methodological Strengths
- Very large prospective cohort with long follow-up (median 13 years) and hard cardio-renal endpoints.
- Stratified analyses by IGF-1 tertiles with multivariable Cox models and subgroup consistency checks.
Limitations
- Observational design limits causal inference; residual confounding is possible.
- Single baseline IGF-1 measurement and potential misclassification of MASLD phenotypes may attenuate associations.
Future Directions: Validate IGF-1–augmented risk models in external cohorts and test whether modifying IGF-1 axis or intensifying preventive care in low-IGF-1 MASLD reduces cardio-renal events.
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) increases cardiovascular and kidney disease risk. Insulin-like growth factor 1 (IGF-1) regulates metabolic and vascular function, but its role in long-term cardio-kidney outcomes (CKO) in MASLD remains unclear. This study examined the association between MASLD, IGF-1 levels and CKO. METHODS: In this prospective cohort study, we used data from 214 512 UK Biobank participants without baseline cardiovascular or chronic kidney disease (CKD). Participants were categorized into four groups: no-MASLD and MASLD stratified by age- and sex-specific tertiles of serum IGF-1 (T1-T3). The primary outcome was a composite CKO; secondary outcomes were incident CKD and 3-point major adverse cardiovascular events (3P-MACE). RESULTS: Over a median 13-year follow-up, 20 395 CKOs occurred. MASLD increased event rates across all IGF-1 tertiles (p < 0.001), with a significant interaction observed between MASLD and IGF-1 levels (P for interaction = 0.014). In multivariable Cox models, MASLD remained independently associated with CKO risk, strongest in the lowest IGF-1 tertile (T1: adjusted hazards ratio [aHR], 1.24 [95% CI: 1.18-1.30] vs. no-MASLD). Similar trends were observed for incident CKD (T1: aHR, 1.35 [95% CI: 1.22-1.49]) and 3P-MACE (T1: aHR, 1.26 [95% CI: 1.18-1.35]). Subgroup analyses indicated consistent associations across sex, BMI and diabetes, with stronger effects in participants < 65 years and markedly greater CKD risk among those with baseline albuminuria. CONCLUSION: MASLD independently predicted CKO, particularly among individuals with low IGF-1 levels. Incorporating IGF-1 into clinical evaluations may improve risk stratification beyond conventional metabolic factors.
3. Accelerometer-Derived 'Weekend Warrior' Physical Activity Pattern and Microvascular Risk in Individuals With Type 2 Diabetes and Prediabetes.
Among 12,923 adults with type 2 diabetes or prediabetes and accelerometer data, both weekend warrior and regularly active patterns (≥150 min/week) similarly reduced incident microvascular complications versus inactivity. Benefits extended to DKD, neuropathy, and retinopathy with robust sensitivity analyses.
Impact: Demonstrates that flexible, concentrated activity patterns can deliver microvascular protection, lowering barriers to achieving physical activity targets in diabetes care.
Clinical Implications: Clinicians can endorse flexible weekly activity scheduling (including 1–2 day concentration) to reduce microvascular risks when ≥150 min/week MVPA is achieved.
Key Findings
- Both weekend warrior and regularly active patterns (≥150 min/week MVPA) reduced incident microvascular complications versus inactivity (HR 0.71 and 0.63, respectively).
- Protective associations were consistent for DKD, diabetic neuropathy, and retinopathy, with no significant differences between active patterns.
- Results were robust across alternative MVPA thresholds, subgroup, and sensitivity analyses over 7.88 years’ median follow-up.
Methodological Strengths
- Objective accelerometer-based activity measures minimize recall bias.
- Large prospective cohort with time-to-event modeling and extensive sensitivity analyses.
Limitations
- Observational design; unmeasured confounding and healthy adherer bias are possible.
- Activity patterns may shift over time; baseline or limited-window assessment could misclassify long-term behavior.
Future Directions: Randomized trials testing flexible vs. regular activity scheduling on microvascular endpoints; implementation studies to integrate ‘weekend warrior’ counseling in diabetes care.
OBJECTIVE: To investigate the associations between accelerometer-derived physical activity patterns-specifically the "weekend warrior" (WW) pattern versus regularly distributed activity-and the risk of incident microvascular complications among individuals with type 2 diabetes (T2D) and prediabetes. METHODS: This prospective cohort study utilized data from the UK Biobank, analysing 12 923 adults with T2D and prediabetes who had accelerometer-measured data. Participants were classified into three groups: active WW (≥ 150 min/week; ≥ 50% of moderate-to-vigorous physical activity [MVPA] accumulated on 1-2 days), active regular (≥ 150 min/week but not meeting WW criteria), and inactive (< 150 min/week). Hazard ratio (HR) and 95% confidence interval (CI) for incident microvascular complications and their subtypes (diabetic kidney disease [DKD], neuropathy [DN], and retinopathy [DR]) were estimated using Cox proportional hazards models. RESULTS: Over a median follow-up of 7.88 years, 1235 incident microvascular complications were documented. Compared with the inactive group, both active patterns were associated with similarly reduced risks of microvascular complications (WW: HR 0.71 [95% CI 0.61-0.82]; regularly active: HR 0.63 [95% CI 0.52-0.77]). These protective associations extended consistently to DKD, DN and DR, with no statistically significant differences between WW and regularly active groups (all p > 0.05). Findings were robust across alternative MVPA thresholds, subgroup analyses, and sensitivity analyses. CONCLUSIONS: Concentrating recommended weekly MVPA within 1-2 days offers similar microvascular protection as regularly distributed activity among individuals with T2D and prediabetes, supporting flexible approaches for this high-risk population to achieve weekly activity goals.